Biotech is hard. It also takes a long time
Witness Corbus Pharmaceuticals, which as STAT’s Adam Feuerstein reports, is within weeks of announcing results from a Phase 3 study investigating a drug to treat patients with a chronic, connective tissue disease.
If you don’t remember much about the Corbus drug called lenabasum, it’s probably because the Phase 2 study was completed four years ago. This is a pivotal moment for Corbus, so now’s a good time to reexamine the old lenabasum data and get you up to speed on the study design and expectations for the Phase 3 readout.
No hay comentarios:
Publicar un comentario